

### Market Commentary

U.S. equities extended their advance in August, with the S&P 500 (+2.0%) rising for a fourth consecutive month and the NASDAQ Composite (+1.6%) rising for a fifth, supported by investor optimism around a potential September rate cut by the Federal Reserve. The rally came as U.S. labour market data softened, reinforcing expectations of imminent monetary easing. In Europe, the Euro STOXX 50, Germany Dax and FTSE 100 total return indices returned +0.6%, -0.7% and +1.2%, respectively over August. Australian equities rallied in August (S&P/ASX 300 +3.2%), supported by the Materials, Consumer Discretionary and Utilities sectors, while the Health Care sector was a large detractor.

### Fund Update and Outlook

The Hyperion Australian Growth Companies Fund returned -3.5% (net of fees) in August, underperforming its benchmark (S&P/ASX 300 Accumulation Index) by 6.6%. Lovisa Holdings Ltd., Life360, Inc. and Seek Ltd. saw the strongest share price performance, while James Hardie Industries plc, CSL Ltd. and Wisetech Global Ltd. saw the largest declines. August closed off a mixed reporting season in the domestic market, dominated by one-off impacts and short-termism, which saw highly volatile share price reactions. There were several areas which showed signs of strength, with strong results from Lovisa Holdings Ltd. (Lovisa), Life360, Inc. and Sigma Healthcare Ltd. (Sigma). Lovisa beat expectations on revenue and saw store rollout reaccelerate, adding 131 net new stores in FY25. Life360, Inc. produced a strong result, upgrading guidance and seeing strong monthly active user (MAU) growth continuing with 88m MAUs +25%. Sigma's first consolidated result with Chemist Warehouse was positive, with Chemist Warehouse network sales up 14% year-on-year, materially outpacing the market, underpinned by industry leading like-for-like sales growth of +11% in Australia and +8% Internationally. Many of the areas that disappointed investors were not new, and short-term focused, such as cost-of-living pressures in the U.S. having an impact on several domestic companies, for example James Hardie Industries plc and Cochlear Limited which Hyperion has exposure to. During times of short-term underperformance, we remain confident in our strategy as we hold high-quality businesses with superior long-term structural growth opportunities arising from their sustainable competitive advantage (including a sound business model and an innovative culture). We believe the long-term earnings growth profiles of our portfolio companies remain strong. Sustained excess growth in earnings leads to greater returns to shareholders over the long term. We believe the long-term outlook for our portfolio remains compelling, with projected internal rates of return exceeding their historical averages. Watch our latest insights in our June webinar [HERE](#).

### Objective

Long-term capital growth by investing in high-calibre Australian companies primarily listed within the S&P/ASX 300 at the time of investment.

Please consider the Product Disclosure Statement (PDS) of the Fund, which provides more complete information on risks and fees, in its entirety, and Target Market Determination (TMD) before making an investment decision. The current PDS and TMD of the Fund can be found at <https://www.hyperion.com.au/>. Companies mentioned are illustrative only and not a recommendation to buy or sell any particular security.

### Our Philosophy

High quality, structural growth businesses with strong sustainable competitive advantages produce superior shareholder returns over the long term.


We believe companies in our portfolio have:

- Earnings which will grow or be maintained
- Low debt
- High interest cover
- Sustainable competitive advantages
- High return on capital
- Strong free cash flow
- Organic growth options
- Innovative organisational cultures

### Time Arbitrage Advantage

We employ a 10-year forward looking valuation framework in a world dominated by short-term thinking.

### Growth of \$10,000 Since Inception, Post-Fees



Inception date: 30<sup>th</sup> September 2002. Source: Hyperion Asset Management. Past performance is for illustrative purposes only and is not indicative of future performance.

### Fund Performance

	Portfolio – Net (%)	Benchmark <sup>1</sup> (%)	Excess Performance (%)
1 Month	-3.5	3.2	-6.6
3 Month	3.6	7.2	-3.6
1 Year	8.0	14.9	-6.9
3 Year (p.a.)	14.3	12.8	1.5
5 Year (p.a.)	8.8	12.2	-3.4
7 Year (p.a.)	10.2	9.2	1.0
10 Years (p.a.)	11.7	9.9	1.9
15 Years (p.a.)	11.2	9.2	2.0
20 Years (p.a.)	10.5	7.9	2.6
Inception (p.a.)*	11.5	9.4	2.2
Inception (TR)*^	1126.3	679.5	446.7

1. S&P/ASX 300 Accumulation Index. \*Inception date that Hyperion became Investment Manager: 30<sup>th</sup> September 2002. ^Total return. All p.a. returns are annualised. Returns are net of applicable fees and costs. Past performance is not a reliable indicator of future performance. Data as at 31<sup>st</sup> August 2025. Due to rounding, excess performance figures may not equate perfectly to the difference between Hyperion Australian Growth Companies Performance and the S&P/ASX 300 Accumulation Index Performance.

### Top 5 Holdings

	Portfolio (%)	Benchmark (%)
Cochlear Ltd	10.6	0.7
Xero Ltd	8.8	1.0
Fisher & Paykel Healthcare	7.4	0.2
Wisetech Global Ltd	7.2	0.7
Block, Inc.	6.3	0.2

Companies shown are illustrative only and not a recommendation to buy or sell any particular security.

### Sector Allocation

	Portfolio (%)	Benchmark (%)
Communication Services	8.0	4.0
Consumer Discretionary	4.5	8.3
Financials	20.0	33.4
Health Care	34.7	8.3
Industrials	0.9	7.6
Information Technology	24.6	3.6
Materials	2.7	19.2
Real Estate	2.1	7.0
Cash	2.5	--

Portfolio weights may not sum perfectly to 100.0% due to rounding.

### Market Capitalisation (AUD)

	Pf (%)	Bm (%)	Act. (%)	# Stocks
S&P/ASX 1-20	13.5	59.5	-46.1	4
S&P/ASX 21-50	44.8	17.4	27.4	9
S&P/ASX 51-100	32.2	12.1	20.2	6
S&P/ASX 101-200	6.4	8.2	-1.9	3
S&P/ASX 201-300	0.6	2.8	-2.2	1
Ex S&P/ASX 300	--	--	--	--
Cash	2.5	--	2.5	--
Total	100	100	--	23

Portfolio weights may not sum perfectly to 100.0% due to rounding.

### Top Contributors and Detractors (rolling 12 months)

Contributors	Price change (%)	Avg Weight (%)	Contribution to return (%)
HUB24 Limited	95.6	4.7	3.4
Technology One Limited	74.5	4.2	2.5
Pro Medicus, Ltd.	98.3	1.6	1.5
Xero Limited	14.5	10.1	1.2
Life360, Inc.	44.7	0.6	1.0

Detractors	Price change (%)	Avg Weight (%)	Contribution to return (%)
CSL Limited	-30.7	6.3	-2.2
James Hardie Industries	-43.4	3.3	-2.0
Guzman y Gomez Ltd.	-28.9	3.7	-0.9
Domino's Pizza Enterprises*	-43.5	1.8	-0.7
IDP Education Ltd*	-46.7	0.7	-0.7

Companies shown are illustrative only and not a recommendation to buy or sell any particular security.

\*Company no longer held in the portfolio

### Fund Characteristics

<b>Universe</b>	<b>S&amp;P/ASX 300</b>
<b>Launch</b>	Managed by Hyperion since September 2002, launched October 1996
<b>Risk/Return Profile</b>	The Fund's risk band is 7 (very high)
<b>Fees</b>	MER 0.95%
<b>Distribution</b>	AUD 1.8651 CPU at 30 June 2025 AUD 1.3594 CPU at 30 September 2024 AUD 4.6618 CPU at 30 June 2024 AUD 0.1283 CPU at 31 March 2024
<b>Fund Size</b>	\$2,512.9 million
<b>APIR Code</b>	BNT0003AU

The Fund's PDS contains more complete information on risks and fees

All data as at 31<sup>st</sup> August 2025



CERTIFIED BY RIAA

### RIAA Certified Fund

The Hyperion Australian Growth Companies Fund has been certified by the Responsible Investment Association Australasia (RIAA) according to the strict operational and disclosure practices required under the Responsible Investment Certification Program. See [www.responsiblereturns.com.au](http://www.responsiblereturns.com.au) for details and the last page of this document for disclaimers.

## Portfolio Holdings Update

### CSL Ltd (CSL-AU)

Primary Exchange  
GICS Sector  
Market Cap (AU\$m)

ASX  
Health Care  
103,084



CSL Ltd. (CSL) reported a mixed FY25 result, with weaker-than-expected growth in the core immunoglobulin business, attributed to short-term/one-off factors (the loss of a large UK tender, and the impact of US Medicare Part D reforms); and more conservative guidance on the timing (not the quantum) of the Behring gross margin recovery. This was partly offset by strength in the Vifor business.

The Seqirus demerger (as a stand-alone ASX-listed company) was a surprise but appears to be well-considered within the new operating model, which focuses on removing complexity by combining the commercial and medical functions of the Behring and Vifor businesses, enabling closer collaboration between the R&D, business development and commercialisation teams.

### Pro Medicus Ltd (PME-AU)

Primary Exchange  
GICS Sector  
Market Cap (AU\$m)

ASX  
Health Care  
31,229



Pro Medicus Ltd. (PME) reported a strong FY25 result at the top and bottom lines (Group revenue +31.9% and EBIT +45%), as well as announcing plans to release a natively-developed digital pathology product this calendar year (following the launch of its cardiology product in FY25). With a modern, cloud-based enterprise imaging product suite including modules for radiology, cardiology and digital pathology, PME is well-placed to continue taking share of the U.S. hospital market (as at FY25 it has approximately 10% of the addressable market under contract). PME's CEO confirmed the pipeline remains strong with new opportunities spanning all key market segments including Academic Medical Centres, Integrated Delivery Networks (IDNs) and the private market.

### Guzman y Gomez Ltd Ltd (GYG-AU)

Primary Exchange  
GICS Sector  
Market Cap (AU\$m)

ASX  
Consumer Discretionary  
2,596



Guzman y Gomez's (GYG) FY25 result undershot analyst expectations with the company investing more in the short-term into overhead than expected by sell-side analysts. This was compounded by a weak trading update for the start of FY26. Sales per store growth slowed from high-single digits to +3.7% in July / August, with the company cycling a strong period last year. Sales growth is expected to rebound later in the calendar year with new product releases and marketing investment. The company's rollout continues in line with expectations. While the market balked, we view negative surprises in the result as incremental and unimpactful to our long-term expectations. We like management's focus on delivering a superior value proposition to its customers over delivering short-term earnings "beats"; GYG has a great product, plenty of white space in Australia, and ample growth levers to pull over the coming years.


**CONTACT US**

**HYPERION DISTRIBUTION**


Jolon Knight  
Mob: 0414 805 862  
Jolon.knight@hyperion.com.au

**INVESTOR SERVICES**

Tel: 1300 497 374  
Investorservices@hyperion.com.au



**Awarded Fund Manager of the Year – Overall**  
Morningstar 2025 Awards, Australia.




**Awarded Fund Manager of the Year – Overall**  
Morningstar 2024 Awards, Australia.



**Awarded Fund Manager of the Year – Overall**  
Morningstar 2021 Awards, Australia.



**Awarded Fund Manager of the Year – Domestic Equities Large Cap Category**  
Morningstar 2021 Awards, Australia.



**Awarded Fund Manager of the Year – Domestic Equities Large Cap Category**  
Morningstar 2020 Awards, Australia.

**DISCLAIMER – HYPERION AUSTRALIAN GROWTH COMPANIES FUND**

This communication is prepared by Hyperion Asset Management Limited (ABN 80 080 135 897 AFSL 238 380) ('Hyperion'), as the investment manager of the Hyperion Australian Growth Companies Fund (ARSN 089 548 443) ('the Fund'). Pinnacle Fund Services Limited (ABN 29 082 494 362 AFSL 238 371) ('PFSL') is the product issuer of the Fund. PFSL is not licensed to provide financial product advice. PFSL is a wholly-owned subsidiary of the Pinnacle Investment Management Group Limited ('Pinnacle') (ABN 22 100 325 184). The Product Disclosure Statement ('PDS') and Target Market Determination ('TMD') of the Fund is available at <https://www.hyperion.com.au/>. Any potential investor should consider the PDS and TMD before deciding whether to acquire, or continue to hold units in, the Fund. For historic TMDs please contact Pinnacle client service Phone 1300 010 311 or Email [service@pinnacleinvestment.com](mailto:service@pinnacleinvestment.com).

This communication is for general information only. It is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. It has been prepared without taking account of any person's objectives, financial situation or needs. Any persons relying on this information should obtain professional advice before doing so. Past performance is for illustrative purposes only and is not indicative of future performance. Unless otherwise specified, all amounts are in AUD. Due to rounding, numbers presented throughout this report may not sum precisely to the total indicated and performance percentages may not precisely reflect the absolute returns.

Whilst Hyperion, PFSL and Pinnacle believe the information contained in this communication is reliable, no warranty is given as to its accuracy, reliability or completeness and persons relying on this information do so at their own risk. Subject to any liability which cannot be excluded under the relevant laws, Hyperion, PFSL and Pinnacle disclaim all liability to any person relying on the information contained in this communication in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information. This disclaimer extends to any entity that may distribute this communication.

Any opinions and forecasts reflect the judgment and assumptions of Hyperion and its representatives on the basis of information available as at the date of publication and may later change without notice. Any projections contained in this presentation are estimates only and may not be realised in the future.

Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained in this communication is prohibited without obtaining prior written permission from Hyperion. Pinnacle and its associates may have interests in financial products and may receive fees from companies referred to during this communication.

This may contain the trade names or trademarks of various third parties, and if so, any such use is solely for illustrative purposes only. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with, endorsement by, or association of any kind between them and Hyperion.

Morningstar Awards 2025 ©. Morningstar, Inc. All Rights Reserved.

Awarded to Hyperion Asset Management for Overall Fund Manager of the Year, Australia.

Awarded to Hyperion Australian Growth Companies Fund for Fund Manager of the Year – Domestic Equities – Large Cap, Australia.

Awarded to Hyperion Small Growth Companies Fund for Fund Manager of the Year - Domestic Equities - Small Caps, Australia.

Awarded to Hyperion Global Growth Companies Fund for Fund Manager of the Year – Global Equities , Australia

Morningstar Awards 2024 ©. Morningstar, Inc. All Rights Reserved.

Awarded to Hyperion Asset Management for Overall Fund Manager of the Year, Australia.

Awarded to Hyperion Small Growth Companies Fund for Fund Manager of the Year - Domestic Equities - Small Caps, Australia.

Morningstar Awards 2021 ©. Morningstar, Inc. All Rights Reserved.

Awarded to Hyperion Asset Management for Overall Fund Manager of the Year, Australia.

Awarded to Hyperion Asset Management for Fund Manager of the Year – Domestic Equities – Large Cap

Awarded to Hyperion Asset Management for Fund Manager of the Year - Domestic Equities - Small Caps, Australia.

Morningstar Awards 2020 ©. Morningstar, Inc. All Rights Reserved.

Awarded to Hyperion Asset Management for Fund Manager of the Year – Domestic Equities – Large Cap

The Responsible Investment Certification Program does not constitute financial product advice. Neither the Certification Symbol nor RIAA recommends to any person that any financial product is a suitable investment or that returns are guaranteed. Appropriate professional advice should be sought prior to making an investment decision. RIAA does not hold an Australian Financial Services Licence.

Hyperion neither provided nor was given compensation in relation to the above-mentioned award/s, however Hyperion pays a licensing fee in order to be able to display awards' logos. Disclaimers specific to awards received by Hyperion can be viewed at: <https://www.hyperion.com.au/awards-and-ratings>